Immune Design is a late-stage immunotherapy company. The immunotherapy technology works by using a body’s immune system to fight diseases.
Its cancer vaccine works by harvesting cancer antigens from tumors and putting them into a vaccine to treat cancer patients. In addition, the company is working to develop vaccines for allergies and infectious diseases.
“Scientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development,” said Roger Perlmutter, MD, PhD, president of Merck Research Laboratories. “This acquisition builds upon Merck’s industry-leading programs that harness the power of the immune system to prevent and treat disease.”
Under the terms of the acquisition, Merck will acquire all outstanding shares of Immune Design.
The transaction is expected to close in the second quarter of this year.
More articles on pharmacy:
FTC settles with Teva over ‘pay-for-delay’ deals
Top 10 fatal or harmful prescribing errors
Civica Rx will start as middleman for drugmakers, hospitals, Bloomberg says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.